Jordan E. Pinsker
A5067199927- Diabetes Management and Research
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Diabetes Treatment and Management
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Gestational Diabetes Research and Management
- Mobile Health and mHealth Applications
- Diabetes Management and Education
- Cardiovascular Function and Risk Factors
- Wireless Body Area Networks
- Sexual Differentiation and Disorders
- Health and Lifestyle Studies
- Connective tissue disorders research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Adrenal Hormones and Disorders
- Thyroid Disorders and Treatments
- Liver Disease Diagnosis and Treatment
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diet and metabolism studies
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Hormonal Regulation and Hypertension
- Transgenic Plants and Applications
- Parkinson's Disease Mechanisms and Treatments
- Electrochemical sensors and biosensors
- Obesity, Physical Activity, Diet
Tandem Diabetes Care (United States)
2023-2025
Sansum Diabetes Research Institute
2015-2024
Diabetes Care Center
2024
Icahn School of Medicine at Mount Sinai
2023
Harvard University
2015-2023
University of Tampa
2020
The Royal Melbourne Hospital
2019
Odense University Hospital
2019
University of Minnesota Rochester
2018
Tripler Army Medical Center
2009-2017
Closed-loop systems that automate insulin delivery may improve glycemic outcomes in patients with type 1 diabetes.
This study evaluated a new insulin delivery system designed to reduce when trends in continuous glucose monitoring (CGM) concentrations predict future hypoglycemia.Individuals with type 1 diabetes (n = 103, age 6-72 years, mean HbA1c 7.3% [56 mmol/mol]) participated 6-week randomized crossover trial evaluate the efficacy and safety of Tandem Diabetes Care t:slim X2 pump Basal-IQ integrated Dexcom G5 sensor predictive low-glucose suspend algorithm (PLGS) compared sensor-augmented (SAP)...
Advances in diabetes technology have transformed the treatment paradigm for type 1 diabetes, yet burden of disease is significant. We report on a pivotal safety study first tubeless, on-body automated insulin delivery system with customizable glycemic targets.This single-arm, multicenter, prospective enrolled 112 children (age 6-13.9 years) and 129 adults 14-70 years). A 2-week standard therapy phase (usual regimen) was followed by 3 months delivery. Primary outcomes were incidence severe...
To evaluate two widely used control algorithms for an artificial pancreas (AP) under nonideal but comparable clinical conditions.After a pilot safety and feasibility study (n = 10), closed-loop (CLC) was evaluated in randomized, crossover trial of 20 additional adults with type 1 diabetes. Personalized model predictive (MPC) proportional integral derivative (PID) were compared supervised 27.5-h CLC sessions. Challenges included overnight after 65-g dinner, response to 50-g breakfast,...
Background: In the past few years, artificial pancreas—the commonly accepted term for closed-loop control (CLC) of blood glucose in diabetes—has become a hot topic research and technology development. summer 2014, we initiated 6-month trial evaluating safety 24/7 CLC during free-living conditions. Research Design Methods: Following an initial 1-month Phase 1, 14 individuals (10 males/4 females) with type 1 diabetes at three clinical centers United States one Italy continued 5-month 2, which...
Background: The t:slim X2™ insulin pump with Control-IQ™ technology, an advanced hybrid closed-loop system, became available in the United States early 2020. Real-world outcomes use of this system have not yet been comprehensively reported. Methods: Individuals type 1 diabetes (T1D) (≥14 years age) who had ≥21 days usage data were invited via email to participate. Participants completed psychosocial questionnaires (Technology Acceptance Scale [TAS], well-being index [WHO-5], and Diabetes...
OBJECTIVE To evaluate the efficacy of a portable, wearable, wireless artificial pancreas system (the Diabetes Assistant [DiAs] running Unified Safety System) on glucose control at home in overnight-only and 24/7 closed-loop (CLC) modes patients with type 1 diabetes. RESEARCH DESIGN AND METHODS At six clinical centers four countries, 30 participants 18–66 years old diabetes (43% female, 96% non-Hispanic white, median duration 19 years, A1C 7.3%) completed study. The protocol included 2-week...
Objective: To assess the efficacy and safety of closed-loop control (CLC) insulin delivery system in adolescents young adults with type 1 diabetes. Research Design Methods: Prespecified subanalysis outcomes aged 14–24 years old diabetes a previously published 6-month multicenter randomized trial. Participants were randomly assigned 2:1 to CLC (Tandem Control-IQ) or sensor augmented pump (SAP, various pumps+Dexcom G6 CGM) followed for 6 months. Results: Mean age 63 participants was 17 years,...
OBJECTIVE There are no commercially available hybrid closed-loop insulin delivery systems customized to achieve pregnancy-specific glucose targets in the U.S. This study aimed evaluate feasibility and performance of at-home use a zone model predictive controller–based system for pregnancies complicated by type 1 diabetes (CLC-P). RESEARCH DESIGN AND METHODS Pregnant women with using pumps were enrolled second or early third trimester. After sensor wear collecting run-in data on personal pump...
Artificial pancreas (AP) systems are best positioned for optimal treatment of type 1 diabetes (T1D) and currently being tested in outpatient clinical trials. Our consortium developed a novel adaptive AP an outpatient, single-arm, uncontrolled multicenter trial lasting 12 weeks.Thirty adults with T1D completed continuous glucose monitor (CGM)-augmented 1-week sensor-augmented pump (SAP) period. After the was started, basal insulin delivery settings used by initialization were adapted weekly,...
Closed-loop control (CLC) relies on an individual's open-loop insulin pump settings to initialize the system. Optimizing before using CLC usually requires significant time and effort.The objective was investigate effects of a one-time algorithmic adjustment basal rate carbohydrate ratio performance CLC.This study reports multicenter, outpatient, randomized, crossover clinical trial.Thirty-seven adults with type 1 diabetes were enrolled at three sites.Each subject's subject based week (i.e.,...
The safety and feasibility of the OmniPod personalized model predictive control (MPC) algorithm in adult, adolescent, pediatric patients with type 1 diabetes were investigated.This multicenter, observational trial included a 1-week outpatient sensor-augmented pump open-loop phase 36-h inpatient hybrid closed-loop (HCL) announced meals ranging from 30 to 90 g carbohydrates limited physical activity. Patients aged 6-65 years HbA1c between 6.0% 10.0% eligible. investigational system modified...
Background: Closed-loop control (CLC) has been shown to improve glucose time in range and other metrics; however, randomized trials >3 months comparing CLC with sensor-augmented pump (SAP) therapy are limited. We recently reported outcomes from the 6-month international Diabetes Closed-Loop (iDCL) trial; we now report patient-reported (PROs) this iDCL trial. Methods: Participants were 2:1 (N = 112) versus SAP 56) completed questionnaires, including Hypoglycemia Fear Survey, Distress Scale...
Background: The artificial pancreas (AP) has the potential to improve glycemic control in adolescents. This article presents first evaluation adolescents of Zone Model Predictive Control and Health Monitoring System (ZMPC+HMS) AP algorithms, their a supervised outpatient setting with frequent exercise. Materials Methods: Adolescents type 1 diabetes underwent 3 days closed-loop (CLC) hotel ZMPC+HMS algorithms on Diabetes Assistant platform. Subjects engaged twice-daily exercise, including...
OBJECTIVE As artificial pancreas (AP) becomes standard of care, consideration extended use insulin infusion sets (IIS) and continuous glucose monitors (CGMs) vital. We conducted an outpatient randomized crossover study to test the safety efficacy a zone model predictive control (zone-MPC)–based AP system versus sensor augmented pump (SAP) therapy in which IIS CGM failures were provoked via wear 7 21 days, respectively. RESEARCH DESIGN AND METHODS A smartphone-based was used by 19 adults...
Background: The primary focus of artificial pancreas (AP) research has been on technical achievements, such as time in range for glucose levels or prevention hypoglycemia. Few studies have attempted to ascertain the expectations users AP technology. Subjects and Methods: Persons with type 1 diabetes parents children were invited take part an online survey concerning future use was advertised via Twitter, Facebook, DiabetesMine, plus advocacy groups charities including INPUT, Diabetes UK,...
Development of an effective artificial pancreas (AP) controller to deliver insulin autonomously people with type 1 diabetes mellitus is a difficult task. In this paper, three enhancements clinically validated AP model predictive (MPC) are proposed that address major challenges facing automated blood glucose control, and then evaluated by both in silico tests clinical trials. First, the core insulin-blood dynamics utilized MPC expanded medically inspired personalization scheme improve...
OBJECTIVE Assess the efficacy of inControl AP, a mobile closed-loop control (CLC) system. RESEARCH DESIGN AND METHODS This protocol, NCT02985866, is 3-month parallel-group, multicenter, randomized unblinded trial designed to compare CLC with sensor-augmented pump (SAP) therapy. Eligibility criteria were type 1 diabetes for at least year, use insulin pumps 6 months, age ≥14 years, and baseline HbA1c <10.5% (91 mmol/mol). The study was assess two coprimary outcomes: superiority over SAP...
There is an unmet need for a modular artificial pancreas (AP) system clinical trials within the existing regulatory framework to further AP research projects from both academia and industry. We designed, developed, tested interoperable (iAPS) smartphone app that can interface wirelessly with leading continuous glucose monitors (CGM), insulin pump devices, decision-making algorithms while running on unlocked smartphone.After algorithm verification, hazard mitigation analysis, complete...
OBJECTIVE Limited information is available about glycemic outcomes with a closed-loop control (CLC) system compared predictive low-glucose suspend (PLGS) system. RESEARCH DESIGN AND METHODS After 6 months of use CLC in randomized trial, 109 participants type 1 diabetes (age range, 14–72 years; mean HbA1c, 7.1% [54 mmol/mol]) were randomly assigned to (N = 54, Control-IQ) or PLGS 55, Basal-IQ) groups for 3 months. The primary outcome was continuous glucose monitor (CGM)-measured time range...
Objective: The aim of this study was to evaluate the impact on pediatric care Pacific Asynchronous TeleHealth (PATH) system, a provider-to-provider teleconsultation platform utilized by military medical facilities throughout Region. This review focuses access care, quality and cost savings for Department Defense as result ongoing development PATH system from 2006 2009. Methods: is retrospective 1,000 consecutive teleconsultations occurring January March Three subspecialists reviewed...